Özlem Türeci to Time Factors
This is a "connection" page, showing publications Özlem Türeci has written about Time Factors.
Connection Strength
0.045
-
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018 09; 100:17-26.
Score: 0.035
-
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
Score: 0.010